Journal profile · PHARMACOLOGY & PHARMACYTOXICOLOGY&nb-TOXICOLOGY
BMC Pharmacology & Toxicology
ISSN 2050-6511 · BioMed Central · ENGLAND · Founded 2012
BMC Pharmacology & Toxicology: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.51; fully open access; APC about USD 3,190; median 122 days to acceptance (113 articles, last 24 months); 240 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
BMC Pharmacology & Toxicology is published by BioMed Central and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Pharmacovigilance and Adverse Drug Reactions, Nitric Oxide and Endothelin Effects and Drug-Induced Hepatotoxicity and Protection, together about 22.7% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
BMC Pharmacology and Toxicology is an open access, peer-reviewed journal that considers articles on all aspects of chemically defined therapeutic and toxic agents. The journal welcomes submissions from all fields of experimental and clinical pharmacology including clinical trials and toxicology. BMC Pharmacology and Toxicology welcomes submissions covering the following broad areas of research. Basic pharmacology We consider studies that focus on receptor pharmacology, signal transduction, pharmacokinetics and pharmacogenomics relating to all organ systems. Clinical pharmacology We consider research submissions that focus on all areas of clinical pharmacology including rational prescribing, pharmacoeconomics, pharmacovigillance, pharmacoepidemiology and clinical trials. Computational, in silico and modeling studies We consider studies that focus on computational simulation including the analysis of structure-activity relationships, molecular modeling and data mining. Drug design, discovery and delivery We consider research that focus on research relating to novel chemical entity design, screening and delivery. Toxicology We consider manuscripts that focus on pharmaceutical, molecular and regulatory toxicology. As a BMC Series journal, BMC Pharmacology and Toxicology does not make editorial decisions based on the perceived interest or potential impact of a study. Manuscripts are considered for publication if they are scientifically valid. For research articles, this includes having a clearly defined and sound research question, appropriate methodology and analysis, and adherence to community-agreed standards relevant to the field.
From the journal's Aims & Scope
Research area (LetPub): PHARMACOLOGY & PHARMACYTOXICOLOGY&nb-TOXICOLOGY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Pharmacovigilance and Adverse Drug ReactionsPharmacology, Toxicology and Pharmaceutics8.9%
- Nitric Oxide and Endothelin EffectsMedicine8.3%
- Drug-Induced Hepatotoxicity and ProtectionPharmacology, Toxicology and Pharmaceutics5.5%
- Phosphodiesterase function and regulationBiochemistry, Genetics and Molecular Biology5.1%
- Receptor Mechanisms and SignalingBiochemistry, Genetics and Molecular Biology4.9%
- Pharmaceutical Practices and Patient OutcomesMedicine4.7%
- Diabetes Treatment and ManagementMedicine4.5%
- Poisoning and overdose treatmentsMedicine4.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Toxicology | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Toxicology | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Toxicology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASCAB AbstractsPublisher website
Other: Google Scholar, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.51LetPub ·
- Impact factor (publisher) 2025
- 3.5Publisher website ·
- 5-year impact factor (publisher) 2025
- 3.5Publisher website ·
- CiteScore 2026-06
- 4.1LetPub ·
- SJR 2026-06
- 0.75LetPub ·
- SNIP 2026-06
- 0.97LetPub ·
- h-index
- 23LetPub ·
- h-index
- 62OpenAlex ·
- i10-index
- 650OpenAlex ·
- 2-year mean citedness
- 3.28OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 98.79%LetPub ·
Volume
- Articles per year
- 239LetPub ·
- Downloads per year (publisher) 2025
- 1,300,000Publisher website ·
Articles by year OpenAlex count · 1,673 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 153 | 153 | 46 |
| 2025 | 240 | 240 | 840 |
| 2024 | 102 | 102 | 738 |
| 2023 | 82 | 82 | 799 |
| 2022 | 98 | 98 | 1,276 |
| 2021 | 72 | 72 | 1,570 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
122 daysMedian, submission to acceptance · P25–P75 81 days – 176 days
- Acceptance to online
- median 12 days (113 articles)
- Submission to online
- median 147 days
- Sample
- 113 articles with submission and acceptance dates (421 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 12 weeksLetPub ·
- Submission to first decision
- 16 daysPublisher website ·
- Submission to publication (journal-reported)
- about 12 weeksDOAJ ·
- Peer review
- Open peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 2,690 / USD 3,190 / GBP 2,390 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 3,090 / EUR 2,590 / GBP 2,290 | — | — | |
| LetPub | GBP 2,090 / USD 2,890 / EUR 2,390 | Yes | — | |
| Publisher website | GBP 2,390 / USD 3,190 / EUR 2,690 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers3, by deadline
Publisher websitePolicy excerpts from the journal's websiteData availability, License & copyright, Open access, Peer review
- Data availability Formatting the 'Availability of data and materials' section of your manuscript
Data sharing strongly encouraged or required Model summary
The following format for the 'Availability of data and materials section of your manuscript should be used:
Source ↗Publisher website ·- License & copyright Licensing and copyright
Open access under CC BY-NC-ND or CC BY licence Model summary
Creative Commons licences Open access articles in Springer Nature journals are published under Creative Commons licences. These provide an industry-standard framework to support easy re-use of open access material. Under Creative Commons licences, authors retain copyright of their articles. BMC Pharmacology and Toxicology articles are published open access under a CC BY-NC-ND (Creative Commons Att…
Source ↗Publisher website ·- Open access Benefits of open access
Publishing open access (OA) offers a number of benefits, including greater reach and readership for your work: Cited more 1.6x more citations of OA articles than non-OA articles across all subjects Downloaded more 4x more downloads of OA articles than non-OA articles Greater impact 2.5x more Altmetric attention. OA articles attracted 1.9x more news mentions and 1.2x more policy mentions Open acces…
Source ↗Publisher website ·- Peer review Peer review policy
Suggesting peer reviewers in cover letter with institutional email addresses or ORCID/Scopus ID Model summary
Peer review is the process used to evaluate the quality of a manuscript before publication. Independent researchers in the relevant field assess submitted manuscripts to check their validity and robustness. Their feedback guides editors in making publication decisions. Typically, two or more experts evaluate each manuscript based on three main criteria: scientific robustness: is the research metho…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- BioMed Central
- Country or region
- ENGLAND
- Language
- English
- Founded
- 2012
- ISSN
- 2050-6511
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about BMC Pharmacology & Toxicology
What CAS zone is BMC Pharmacology & Toxicology in?
In the 2025 upgraded edition of the CAS Journal Ranking, BMC Pharmacology & Toxicology is in Zone 3 of Medicine, and in Zone 2 of the minor category Toxicology / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of BMC Pharmacology & Toxicology?
The latest impact factor listed by LetPub is 3.51; CiteScore 4.1, h-index 62.
How long does peer review take at BMC Pharmacology & Toxicology?
Based on the dates recorded on 113 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 122 days (interquartile range 81–176 days); authors report an average review time of about 12 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index BMC Pharmacology & Toxicology?
According to LetPub and DOAJ records, BMC Pharmacology & Toxicology is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, Embase, CAS and CAB Abstracts; that list has not been checked against each database.
Is BMC Pharmacology & Toxicology open access, and what is the APC?
BMC Pharmacology & Toxicology is a fully open-access journal. APC about USD 3,190.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .